“As boardrooms prepare for risks on the horizon, it is encouraging...
Category:
Eco/Invest/Demography
Latest
Robust improvement in Gujarat’s public health infra in last two decades: govt data
Finance Minister Kanubhai Desai had also announced to double the...
Deepfakes deceive voters from India to Indonesia before elections
Countries including India, Indonesia and Bangladesh have recently...
India extends nationwide lockdown,to allow relaxations in lower-risk zones
The biggest and most economically-important cities, including New Delhi, Mumbai, Bengaluru, Chennai and Ahmedabad, would all be classed as red zones, infection hotspots, and kept under strict lockdown.
Maker of coronavirus trial drug aims for wide distribution – Gilead CEO
Gilead Sciences, which manufactures remdesivir, is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once it is approved, Chief Executive Officer Daniel O’Day said on Friday. Interest in...
U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir
A draft study abstract released inadvertently by the World Health Organization (WHO) last week said remdesivir failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream. The drugmaker said the findings were inconclusive because the study was terminated early.
half of world’s workforce risks losing livelihoods in pandemic: ILO
“It shows I think in the starkest possible terms that the jobs employment crisis and all of its consequences is deepening by comparison with our estimates of 3 weeks ago,” ILO Director-General Guy Ryder told a briefing, foreseeing a “massive” poverty impact.Already, wages of the world’s 2 billion informal workers plunged by an estimated global average of 60% in the first month that the crisis unfolded in each region, the ILO said.
India’s Glenmark to conduct trials for potential COVID-19 drug
Favipiravir, manufactured under the brand name Avigan by a unit of Japan’s Fujifilm Holdings Corp (4901.T) and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.
“After having successfully developed the API and the formulations … Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India,” Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement.
France drafting future insurance backstop for pandemics
A working group set up by French Finance Minister Bruno Le Maire, which includes lawmakers, business lobbies, France’s insurance association and public reinsurer CCR, is examining further insurance options to cover events like pandemics – and aims to put forward proposals by the first half of June, Axa’s Renaud Guidee told Reuters.
Swiss Re swings to 1st-qtr loss as Covid-19 Pandemic bites
Meanwhile,Joachim Wenning,chief executive,Munich Re,said the short- and long-term costs of the coronavirus pandemic are significant but his company is economically fit as it deals with it, the company’s said Wednesday.
COVID-19 death toll rises to 1,074; cases 33,050,MHA allows stranded to return home
MHA guidelines for movement of stranded persons
-States/UTs to appoint nodal authorities and develop standard protocol for receiving and sending persons
-All stranded persons are to be registered with the sending and receiving states
-In case of inter-state movement of such persons, consult each other and mutually agree to the movement by road
IRDA asks general insurers to guide India Inc on managing their “Property Policies”post lockdown
“The general insurers have been advised by the IRDAI to inform the policyholders of how the relevant clause(s) would apply beyond 3rd May, 2020 in all policies and what action is needed by the policyholders to avail of uninterrupted coverage,’’ said IRDAI on Thursday..
Top insurers face lawsuit from UK hospitality sector on rejected biz interruption claims
Any successful claim will hinge partly on whether the lockdown triggers a clause in business interruption policies designed for insured premises that cannot be used because of restrictions imposed by a public authority, experts say.
The Financial Conduct Authority (FCA) said earlier this month that most insurance policies bought by smaller British companies do not cover the coronavirus-related disruption, but that those that do should pay out quickly.